Table 1.
Correlations of CSF3 expression with clinical features of high-grade glioma in The Cancer Genome Atlas cohort.
| Variables | Total (n = 298) | Low (n = 137) | High (n = 161) | P-value |
|---|---|---|---|---|
| Age (years), n (%) | <0.001 | |||
| <60 | 197 (66) | 107 (78) | 90 (56) | |
| ≥60 | 101 (34) | 30 (22) | 71 (44) | |
| Gender, n (%) | 0.048 | |||
| Female | 120 (40) | 64 (47) | 56 (35) | |
| Male | 178 (60) | 73 (53) | 105 (65) | |
| Grade, n (%) | <0.001 | |||
| III | 170 (57) | 114 (83) | 56 (35) | |
| IV | 128 (43) | 23 (17) | 105 (65) | |
| IDH status, n (%) | <0.001 | |||
| Wild type | 169 (57) | 54 (39) | 115 (71) | |
| Mutant | 129 (43) | 83 (61) | 46 (29) | |
| Chr 1p_19q co-deletion, n (%) | 0.043 | |||
| No | 248 (83) | 107 (78) | 141 (88) | |
| Yes | 50 (17) | 30 (22) | 20 (12) | |
| MGMT promoter status, n (%) | <0.001 | |||
| Unmethylated/Unknown | 118 (40) | 34 (25) | 84 (52) | |
| Methylated | 180 (60) | 103 (75) | 77 (48) | |
| Chemotherapy, n (%) | 0.125 | |||
| No | 79 (27) | 30 (22) | 49 (30) | |
| Yes | 219 (73) | 107 (78) | 112 (70) | |
| Radiotherapy, n (%) | 0.023 | |||
| No | 70 (23) | 41 (30) | 29 (18) | |
| Yes | 228 (77) | 96 (70) | 132 (82) |